Drug Trial Radar · NCT07855276
A Study to Explore the Tissue Level Effects of Remibrutinib in Adults With Moderate to Severe HS
Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
Oct 29, 2026
Primary completion
Nov 29, 2027
Study completion Dec 27, 2027
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Oct 2, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to better understand how Bruton's tyrosine kinase (BTK) inhibition with remibrutinib works in hidradenitis suppurativa (HS), a complex inflammatory disease with different types of lesions.
Conditions
- Hidradenitis Suppurativa
Interventions
LOU064Drug
Remibrutinib
PlaceboDrug
matching placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Fold change from baseline in auto-antibodiesTime frame: Baseline, Week 16
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
University Clinical Trials
San Diego, California · Recruiting
Apex Clinical Research Center LLC
Mayfield Heights, Ohio · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.